Company: IMCR
Filing Date: 2025-03-24
Form Type: PRE 14A
Source: 0001140361-25-010035
Chunk: 95

Company: Immunocore Holdings plc
Filing Date: 2025-03-24
Form: PRE 14A
Chunk 95
---
-Date  
 Fair Value of 
 Equity        
 Awards        
 Granted       
 During Year   
 that Vested   
 During Year   
 for Non-PEO   
 NEOs          
 ($)           |     |      Average 
    Change in 
   Fair Value 
    from Last 
 Day of Prior 
      Year to 
 Vesting Date 
  of Unvested 
       Equity 
  Awards that 
       Vested 
  During Year 
  for Non-PEO 
         NEOs 
          ($) |     |       Average 
 Fair Value at 
   Last Day of 
 Prior Year of 
        Equity 
        Awards 
     Forfeited 
   During Year 
   for Non-PEO 
          NEOs 
           ($) |     | Average      
 Value of     
 Dividends or 
 Other        
 Earnings     
 Paid on      
 Equity       
 Awards Not   
 Otherwise    
 Included for 
 Non-PEO      
 NEOs         
 ($)          |     |      Total - 
      Average 
 Inclusion of 
       Equity 
   Values for 
      Non-PEO 
         NEOs 
          ($) |
| 2024 |     |       561,820 |     |   -1,715,283 |     | —             |     |   -2,300,460 |     |    -1,555,955 |     | —            |     |   -5,009,878 |

| (4) | For the relevant fiscal year, represents the cumulative total shareholder return (“TSR”) of our ADSs (each representing one ordinary share) and of the Nasdaq Biotechnology Index (“Peer Group TSR”), which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report for the year ended December 31, 2024. The comparison assumes $100 was invested for the period starting February 5, 2021, through the end of the listed year in our ADSs and in the Nasdaq Biotechnology Index, respectively. Historical stock performance is not necessarily indicative of future stock performance. |

| (5) | The dollar amounts reported represent the amount of net income reflected in our audited financial statements for the applicable year included in our Annual Report for the year ended December 31, 2024. |

64

TABLE OF CONTENTS Required Disclosure of the Relationship Between Compensation Actually Paid and Financial Performance In accordance with Item 402(v) of Regulation S-K, we are providing the following descriptions of the relationships between information presented in the Pay Versus Performance